Event details

7th Frederick E Hargreave Lectureship

Nizar Jarjour


Start 18 November, 2019, 5 PM

End 6 30 PM


50 Charlton Avenue East



No country specified

Miller Auditorium, 2nd Level of the Juravinski Innovation Tower at St. Joseph's Healthcare Hamilton, Hamilton, Ontario.

Contact Info

No contact e-mail provided

No website provided

The Department of Medicine and the Divisions of Respirology and Allergy and Clinical Immunology are pleased to announce the 7th Frederick E. Hargreave Lectureship in Asthma and Allergy to honour the memory of our dear colleague, who passed away on the 15th of June, 2011. Professor Freddy Hargreave was one of the giants of respiratory medicine. His work helped change the way we understand, diagnose and treat asthma, bronchitis and COPD. In doing so, he significantly improved the care of patients throughout the world and his work improved many lives. At the Firestone Clinic, over a 40-year career, he taught many students and fellows from all over the world, many of whom returned home and became internationally recognized in their own right. He made St Joseph’s Hospital and the Firestone Clinic famous around the world, but more importantly, he cared for individual patients in an exemplary manner with unfailing courtesy, dedication, humility, and kindness. He constantly endeavored to bring the health challenges his patients faced every day to the research community in order to find better ways to improve the quality of their lives.

The 2019 Lecture will be delivered by Dr. Nizar Jarjour, a professor of medicine and head of the Division of Allergy, Pulmonary & Critical Care Medicine in the Department of Medicine at the University of Wisconsin. Since 2016, he has taken on the role of president of the UW Medical Foundation, providing physician leadership to nearly 1500 physicians at the University of Wisconsin faculty practice plan. In addition to remaining clinically active, Dr. Jarjour leads an internationally recognized, NIH-funded research program, focused on the mechanisms and treatment of asthma, which is ranked as the top program among all US public universities. His work resulted in nearly 200 papers with more than1000 annual scientific citations. Dr. Jarjour has also served on the American Board of Internal Medicine-Pulmonary Specialty Committee, and the FDA as part of the advisory group on allergy and pulmonary drugs. For more than two decades, Dr. Jarjour served on the leadership team for the UW Institute for Clinical and Translational Research (ICTR), directing the ICTR Clinical and Translational Research Core and chairing the protocol review committee. The role of eosinophils in allergic airway inflammation and remodeling has been a long-standing interest and a focus for his laboratory. His eosinophil research program has made seminal observations related to mechanisms of eosinophil recruitment, activation, and contribution to airway remodeling, asthma severity and exacerbations.

Supported by unrestricted grants from Methapharm, a specialty pharmaceutical company with a focus on the acquisition, licensing, partnering, and promotion of specialty pharmaceutical products in North America.